Sign up to save your podcasts
Or
Share Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Disc Medicine CEO John Quisel describes the process of becoming among the first companies to receive FDA's new Commissioner's National Priority Voucher (CNPV)
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
View all episodes
By BiotechTV
5
44 ratings
He describes how Disc applied for and was awarded a CNPV for Bitopertin, which treats a rare disease that causes extreme sensitivity to sunlight. Plus, quickly ramping up a commercial team, and discussing Disc's two other development programs.
More shows like BiotechTV - News
View all
Planet Money
30,626 Listeners
Odd Lots
1,863 Listeners
a16z Podcast
1,085 Listeners
The Readout Loud
325 Listeners
The Journal.
6,059 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks Friedberg
9,840 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
497 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners